Acute Repetitive Seizures Market To Reach $6.31 Billion By 2030

Acute Repetitive Seizures Market Growth & Trends

The global acute repetitive seizures market size is expected to reach USD 6.31 billion by 2030, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 12.4% during the forecast period. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

 Request a free sample copy or view report summary: Acute Repetitive Seizures Market Report

Acute Repetitive Seizures Market Report Highlights

• Global acute repetitive seizures market size was estimated at USD 2.60 billion in 2022 and is expected to register a CAGR of 12.4% over the forecast period

• The USL-261 segment dominated the market with the largest revenue share in 2022 because a caregiver can administer it without the need for a needle, and it works quickly.

• North America held the largest share in 2022 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures

• Germany is expected to witness robust growth over the forecast period owing to technological advancements in scientific, clinical, and medical fields.

Acute Repetitive Seizures Market Segmentation

Grand View Research has segmented the global acute repetitive seizures market on the basis of product and region:

Acute Repetitive Seizures Product Outlook (Revenue in USD Million, 2018 - 2030)

• USL-261

• NRL-1

• AZ-002

• Diastat Rectal Gel

• Others

Acute Repetitive Seizures Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List Of Key Players in the Acute Repetitive Seizures Market

• UCB S.A. Belgium

• Neurelis, Inc.

• Bausch Health Companies Inc.

• ALEXZA

• VERITON PHARMA